In triple-negative breast cancer (TNBC), inhibiting FAK genetically or with drugs decreases anchorage-independent spheroid cell growth, reduces chemotherapy-dependent CSC enrichment, and delays metastatic outgrowth [99, 103]. This evidence concerns the gene PTK2 and triple-negative breast carcinoma.